30 closest matches · ranked by relevance
Peritoneal Carcinomatosis
Primary: Percentage of Patients That Had at Least One Additional Lesion Detected Under Pegsitacianine Guidance Following CRS That Was Confirmed as Positive for Disease by…
Abdominal Neoplasm · Colonic Neoplasm · Mesothelioma
Primary: Number of Participants With Disease-free Survival
Gastrointestinal Neoplasm
Primary: Progression Free Survival
Gynecologic Cancer · Gynecologic Neoplasms · Peritoneal Carcinomatosis
Primary: Proportion of Participants Who Are Successfully Down Staged to Resectable Based on Peritoneal Carcinomatosis Index (PCI) and Principal Investigator (PI) Discretion…
Peritoneal Carcinomatosis · Colorectal Cancer · Appendiceal Cancer
Primary: Completeness of Cytoreduction
Peritoneal Surface Malignancy
Primary: Dose Limiting Toxicity (DLT) — 0; 0; 0 Participants
Mesothelioma · Peritoneal Mesothelioma
Primary: Major Pathologic (Disease) Response of Tumor to Nivolumab Combined With Ipilimumab Before Surgery
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2
Gastrointestinal and Gynecologic Malignancies
Primary: Rate of Detectable Peritoneal Metastases — 0; 2 percentage of lesions
Peritoneal Carcinomatosis
Primary: The Grouped Miller and Payne (MP) System for Pathological Response: G1 (Minimal Changes and < 30% Cells Tumour Reduction That Includes MP G1-G2), G3 (Microscopic Foci…
Peritoneal Surface Malignancy · Postoperative Adhesion · Bowel Obstruction
Primary: Incidence of Major Intra-abdominal Complications — 4; 11 Participants
Progressive Desmoids Tumors
Primary: Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate). — 84.8; 45.0…
Gastrointestinal Cancer
Primary: Overall Survival (OS) After Hyperthermic Intraperitoneal Chemotherapy — 30.2 Months
Primary Peritoneal Carcinoma · Ovarian Carcinoma · Fallopian Tube Carcinoma
Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants
Fallopian Tube Cancer · Metastatic Cancer · Ovarian Cancer
Primary: 9-month Progression Rate Post-randomization — 0.386; 0.347; 0.245 Porportion of participants — p=0.065
Pancreatic Endocrine Neoplasms
Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants
Peritoneal Damage
Primary: Inflammatory Peritoneal Markers — 0.80; 1.14; 4.26; 3.24 log (pg/ml) — p=0.058
Gastric Cancer · Pancreatic Cancer
Primary: Number of Study Participants With Adequate Percutaneous Lavage Specimen Collection — 70; 2; 4 Participants
Advanced Cancers · Sarcoma
Primary: Recurrence Free Survival — 13.99 months
Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Endometrioid Adenocarcinoma · Fallopian Tube Mucinous Adenocarcinoma
Primary: Median Progression-free Survival — 24.9; 27.3; 26.0 months — p=0.341
Carcinoma of the Appendix · Primary Peritoneal Cavity Cancer
Primary: The Difference in the Number of Grade 3 or 4 Hematologic Toxicities (Leukopenia, Thrombocytopenia, and Neutropenia) Between the Mitomycin C and Oxaliplatin Treatments…
Ovarian Neoplasms · Fallopian Tube Neoplasms · Peritoneal Neoplasms
Primary: Determination of the Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 Participants
Ovarian Carcinoma · Primary Peritoneal Carcinoma
Primary: Progression-free Survival (PFS) — 56 percentage of participants
Colorectal Cancer · Ovarian Cancer · Appendiceal Cancer
Primary: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) and Dose Limiting Toxicities (DLTs) — 4; 5; 19; 36 Participants
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
Colorectal Neoplasms · Peritoneal Neoplasms
Primary: Peritoneal Recurrence Free Survival at 18 Months — 79; 80 participants
Neuroendocrine Tumors · Neuroendocrine Neoplasm of Lung
Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants
Advanced/Metastatic Neuroendocrine Tumors
Primary: Clinical Benefit Rate — 11 Participants
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Median Time to Paracentesis — 28; 14 days — p=0.17
Ovarian Cancer · Primary Peritoneal Cancer
Primary: Phase 1 - Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Carboplatin